A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
about
STAT3: A Novel Molecular Mediator of Resistance to ChemoradiotherapySrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Bone-targeted agents in the treatment of lung cancer.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Fluorescent visualization of Src by using dasatinib-BODIPYThe synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
P2860
Q27003190-DEC4A177-4B11-4869-84C5-86A33761F9E7Q30278774-1190AB3F-8920-475E-9EED-C67F2D451A3DQ34186283-7D36A187-A40A-466F-9DB3-881DE7A028F9Q34432733-D9EABB46-2D7E-4BA9-B151-DE789118126DQ34480200-CB390E06-325D-49B8-A9C6-7DC2AC04DE5BQ35780792-2372E378-AA2E-4000-9D7B-099EFE64C3B3Q36140620-3288B768-8412-4434-9E88-DF58298B81EAQ36557486-C582AA91-E443-41C5-9767-287357F8D347Q38994926-A2209C3B-984B-4A3B-BC6E-16A4ABAB4A28Q47214772-8951A78C-6493-4DFE-AD6A-95978AD9515CQ52839148-59AE5EEE-D710-4403-946A-BDD239E239F2
P2860
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase II trial of saracatini ...... hospital phase II consortium.
@en
type
label
A phase II trial of saracatini ...... hospital phase II consortium.
@en
prefLabel
A phase II trial of saracatini ...... hospital phase II consortium.
@en
P2093
P1433
P1476
A phase II trial of saracatini ...... hospital phase II consortium.
@en
P2093
Frances A Shepherd
Garth Nicholas
Glenwood D Goss
John J Wright
Lindsay Philip
M Neil Reaume
Natasha B Leighl
Scott A Laurie
P356
10.1016/J.CLLC.2013.08.001
P407
P577
2013-10-26T00:00:00Z